Active Ingredient(s):Deutetrabenazine FDA Approved: * April 3, 2017 Pharm Company: *TEVA PHARMS USA INC Category:Neurological Disorders
Deutetrabenazine (trade name Austedo) is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia.
Chemically, deutetrabenazine is an isotopic isomer of tetrabenazine in which six hydrogen atoms have been replaced by deuterium atoms. The incorporation of deuterium slows the rate of drug metabolism, allowing less frequent dosing.
* May have multiple approval dates, manufacturers, or labelers.